Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
MetadataShow full item record
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, embolization, radiation, chemotherapy, immunotherapy and use of other more targeted drugs. In this review, we describe the cellular and molecular effects of current chemotherapy drugs such as gemcitabine, FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and ABRAXANE (nab-Paclitaxel), which have shown a survival benefit, although modest, for pancreatic cancer patients. Nevertheless, gemcitabine remains the standard first-line option for advanced-stage pancreatic cancer patients and, as resistance to the drug has attracted an increasing scientific interest, we deliberate on the main intracellular processes and proteins vital in acquired chemoresistance to gemcitabine. Lastly, our review examines various microenvironmental factors capable of instigating PDAC to develop resistance to chemotherapeutic drugs.
Showing items related by title, author, creator and subject.
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticalsAbrams, S.; Lertpiriyapong, K.; Yang, L.; Martelli, A.; Cocco, L.; Ratti, S.; Falasca, Marco; Murata, R.; Rosalen, P.; Lombardi, P.; Libra, M.; Candido, S.; Montalto, G.; Cervello, M.; Steelman, L.; McCubrey, J. (2018)Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10%. Mutations at ...
The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistanceElaskalani, Omar; Falasca, Marco; Moran, N.; Berndt, Michael; Metharom, Pat (2017)Platelets have been demonstrated to be vital in cancer epithelial-mesenchymal transition (EMT), an important step in metastasis. Markers of EMT are associated with chemotherapy resistance. However, the association between ...
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control studyKho, P.; Fawcett, J.; Fritschi, Lin; Risch, H.; Webb, P.; Whiteman, D.; Neale, R. (2016)Purpose: Studies suggest that aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and statins may reduce risk of some cancers. However, findings have been conflicting as to whether these agents reduce the risk ...